$FOLD News
Last published 1w ago
- 1w agoFOLDBioMarin Pharmaceutical Third Quarter 2026 Conference Call - AMICUS THERAPEUTICS INCEarnings Call TranscriptsHello everyone, thank you for joining us and welcome to the Biomarin third quarter 2026 conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, pl
- 1mo agoFOLDBioMarin - 1773775 - AMICUS THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm Sean Laman, Head of U.S. Mid-Cap Biotech Equity Research here at Morgan Stanley, and welcome to our Global Healthcare Conference. Before we begin, I'll make you aware of some important disclos
- 2mo agoFOLDWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - AMICUS THERAPEUTICS INCEarnings Call TranscriptsThank you so much for joining us for this afternoon's session. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo, and I'm joined by team Biomarin with us today. So we have Greg Freit
- 2mo agoCWENCWEN.CCWEN-CCWEN.A+2Clearway Energy, Inc. Announces Senior Leadership ChangesGlobeNewswirePRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE:CWEN) ("Company", "Clearway") today announced a series of senior leadership appointments: Sarah Rubenstein, Chief
- 3mo agoFOLDCG 46TH ANNUAL GROWTH CONFERENCE - AMICUS THERAPEUTICS INCEarnings Call TranscriptsAll right. Good morning, everyone. Thank you so much for joining us. My name is Whitney Egyem. I'm one of the biotech analysts here at Canaccord. And it's my pleasure to introduce Biomarin Pharmaceutical this morning. An
- 3mo agoFOLDBioMarin Pharmaceutical Second Quarter 2026 Conference Call - AMICUS THERAPEUTICS INCEarnings Call TranscriptsGood afternoon and welcome everyone to the Biomarin Pharmaceutical second quarter 2026 conference call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the
- 6mo agoFOLDBioMarin Pharmaceutical First Quarter 2026 Conference CallAMICUS THERAPEUTICS INCEarnings Call TranscriptsGood afternoon and welcome everyone to the Biomarin Pharmaceutical First Quarter 2026 conference call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the s
- 8mo agoFOLDBioMarin - 1754334AMICUS THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at Berkley's. Very excited to have Biomarin here with us. Certainly a very important year for you with commercial launches and clinical readouts
- 8mo agoFOLDBIOMARIN PHARMACEUTICAL INC. (BMRN) - LEERINK GLOBAL HEALTHCARE CONFERENCEAMICUS THERAPEUTICS INCEarnings Call TranscriptsWelcome to this fireside chat with BioMarin. It's my pleasure to host. I'm Joe Schwartz from the Biopharma Equity Research Team at Lyric Partners, and I'm pleased to be joined by Brian Muller, Chief Financial Officer, an
- 8mo agoFOLDAmicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate UpdatesGlobeNewswire2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J.,
- 9mo agoFOLDAmicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026GlobeNewswirePRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease
- 10mo agoFOLDKBLBPBMPRPHFrom Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning TapeGlobeNewswireDENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies
- 10mo agoBMRNFOLDBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial OutlookPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive...
- 11mo agoAMGNCTORFOLDSNGX+1Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging PopulationsGlobeNewswireAUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with
- 1y agoFOLDAmicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswireQ3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04,
- 1y agoFOLDAmicus Therapeutics to Present at Upcoming Investor Conferences in November 2025GlobeNewswirePRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. 2025
- 1y agoFOLDAmicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025GlobeNewswirePRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to
- 1y agoFOLDAmicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoFOLDNew 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEMGlobeNewswirePRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label
- 1y agoFOLDAmicus Therapeutics to Present at Upcoming Investor Conferences in September 2025GlobeNewswirePRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
- 1y agoSNGXAMGNFOLDTNXP+1Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for InnovatorsPR NewswireAs the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The...
- 1y agoFOLDAmicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoFOLDAmicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswireQ2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance
- 1y agoFOLDAmicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025GlobeNewswirePRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to
- 1y agoFOLDAmicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in JapanGlobeNewswirePRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase
- 1y agoFOLDNew Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and NerveGlobeNewswirePRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of
- 1y agoFOLDAmicus Therapeutics to Present at Upcoming Investor Conferences in June 2025GlobeNewswirePRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies
- 1y agoFOLDAmicus Therapeutics to Present at the Bank of America 2025 Health Care ConferenceGlobeNewswirePRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas,
- 1y agoFOLDAmicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswire1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S.
- 1y agoFOLDDimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United StatesGlobeNewswireAmicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no
- 1y agoFOLDAmicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025GlobeNewswirePRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to
- 1y agoFOLDAmicus Therapeutics to Present at Upcoming Investor Conferences in March 2025GlobeNewswirePRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. TD Cowen
- 1y agoFOLDAmicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate UpdatesGlobeNewswire2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at
- 1y agoFOLDKuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ:FOLD) breached their
- 1y agoFOLDAmicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025GlobeNewswirePRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET
- 1y agoFOLDAmicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025GlobeNewswirePRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual
- 1y agoFOLDAmicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic OutlookGlobeNewswire2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected in
- 1y agoFOLDAmicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswirePRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare
- 2y agoFOLDAmicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoFOLDAmicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate UpdatesGlobeNewswireQ3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total
- 2y agoFOLDAmicus Therapeutics to Present at Upcoming Investor Conferences in November 2024GlobeNewswirePRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
- 2y agoFOLDAmicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024GlobeNewswirePRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET
- 2y agoFOLDAmicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with TevaGlobeNewswirePRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva
- 2y agoFOLDAmicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024GlobeNewswirePRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual
- 2y agoFOLDAmicus Therapeutics Announces Participation at the SSIEM 2024 Annual SymposiumGlobeNewswirePRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced that five posters across its development programs will be included at the Society for the Study of Inborn Errors of
- 2y agoFOLDAmicus Therapeutics to Present at Upcoming Investor Conferences in September 2024GlobeNewswirePRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
- 2y agoFOLDAmicus Therapeutics, Inc. (FOLD) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoFOLDAmicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate UpdatesGlobeNewswireQ2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti® + Opfolda® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total
- 2y agoFOLDAmicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024GlobeNewswirePRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to
- 2y agoFOLDAmicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswirePRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in